Scott j. antonia
Deparment of Immunology
Moffitt Cancer Center
United States of America
Dr. Scott J. Antonia is affiliated to Deparment of Immunology, Moffitt Cancer Center. Dr. Scott J. Antonia is currently providing services as Researcher. Dr. Scott J. Antonia has authored and co-authored multiple peer-reviewed scientific papers and presented works at many national and International conferences. Dr. Scott J. Antonia contributions have acclaimed recognition from honourable subject experts around the world. Dr. Scott J. Antonia is actively associated with different societies and academies. Dr. Scott J. Antonia academic career is decorated with several reputed awards and funding. Dr. Scott J. Antonia research interests include translational research, using his molecular biology and cellular immunology training in the development of immunotherapeutic strategies for the treatment of cancer patients.
Translational research, using his molecular biology and cellular immunology training in the development of immunotherapeutic strategies for the treatment of cancer patients
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2017 Sep 8.
Yuan Z, Fromm A, Ahmed KA, Grass GD, Yang GQ, Oliver DE, Dilling TJ, Antonia SJ, Perez BA. Radiotherapy rescue of a nivolumab-refractory immune response in a patient with PD-L1 negative metastatic squamous cell carcinoma of the lung. Journal of Thoracic Oncology. 2017 May 10.
Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. The Lancet Oncology. 2017 Jul 17.